Researchers wanted to determine if they could safely reduce an 8-week course of conformal radiotherapy and achieve similar efficacy into a 4-week course in men with an intermediate prostate cancer risk . They determined that this shorter (with high dose) regimen was not inferior to conventional radiotherapy and that it did not increase either acute or late toxicities.
meetinglibrary.asco.org/con...
Joel